Vancouver, British Columbia, June 20, 2016 – Altum Pharmaceuticals Inc. (“Altum” or the “Company”), is pleased to announce that it has entered into an agreement with Ortac Capital & Ortac AG (“Ortac), a Zurich based investment intermediates firm, to raise additional growth and working capital for Altum. Ortac, on a best efforts basis, will raise up to $5m Cdn for Altum in the coming weeks. Altum CEO, Ahmad Doroudian, stated “Ortac has provided a strong commitment to our company and we look forward to a mutually beneficial long term relationship.”

Ortac Management stated “We are extremely excited to be working with such a strong caliber of leadership and expertise and have provided Altum with a long term commitment to raise capital as required.”


About Altum Pharmaceuticals Inc.

Altum Pharmaceuticals Inc. is a biopharmaceutical company engaged in clinical and commercial development of novel natural and pharmaceutical compounds, to treat cancer and autoimmune disorders. Altum focuses on development and acquisition of novel products specializing on the commercialization of existing products for cancer and diseases mediated by acute and chronic inflammatory reactions. For more information please visit our website at


About Ortac Capital Corp & Ortac AG

Ortac is a Zurich based investment intermediates firm that raises capital for innovative projects with ultra -strong management with a proven track record. The firm has been involved in this sector for many years and has an extensive network of funders and high net worth individuals throughout Europe and Asia. Ortac is the Lead Manager and official placement agent for Altum Pharmaceuticals Inc.



Certain information in this presentation are forward-looking and relate to Altum’s anticipated financial position, business strategy, events and courses of action. Words or phrases such as “anticipate,” “objective,” “may,” “will,” “might,” “should,” “could,” “can,” “intend,” “expect,” “believe,” “estimate,” “predict,” “potential,” “plan,” “is designed to” or similar expressions suggest future outcomes. Forward-looking statements include, among other things, statements about: sales and operations; our estimates regarding our capital requirements and our need for additional financing; our ability to anticipate the future needs of our customers; our future growth strategy and growth rate and our future intellectual property. Such statements reflect our current views with respect to future events and are based on assumptions and subject to significant risks and uncertainties. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Our actual results, performance or achievements could differ materially from those contemplated, expressed or implied in our statements as a result of various risk factors, including, but not limited to, business, economic and capital market conditions; market conditions and the demand and pricing for our products; our relationships with our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers’ needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; our manufacturing supply chain, including pricing of goods and availability of adequate manufacturing capacity from our manufacturing suppliers; our ability to manage risks inherent in foreign operations; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; our ability to manage cash flow, foreign exchange risk and working capital; our ability to manage our growth; fluctuation in our quarterly operating results; and our dependence on key personnel. Except as required by law, we undertake no obligation to update or revise publicly any forward‑looking statements.